NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
disclaimer for details.
ClinicalTrials.gov Identifier: NCT01649180
(Closed due to prolonged enrollment timelines)
First Posted : July 25, 2012
Results First Posted : April 20, 2017
Last Update Posted : May 23, 2017
Information provided by (Responsible Party):
Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Renal Cell Carcinoma
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
Layout table for Results Point of Contact information
ECOG-ACRIN Biostatistics Center
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14(22):7272-83. doi: 10.1158/1078-0432.CCR-08-0652.
Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007 Nov;8(11):975-84. Epub 2007 Oct 23.
Layout table for additonal information
History of Changes
Other Study ID Numbers:
WS1512227 ( Other Grant/Funding Number: Pfizer )
July 21, 2012
July 25, 2012
Results First Submitted:
December 6, 2016
Results First Posted:
April 20, 2017
Last Update Posted:
May 23, 2017